Korean Journal of Radiology

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

Efficacy and Safety of Ultrasound-Guided Radiofrequency Ablation for Primary Hyperparathyroidism: A Prospective Study

  • Hui-hui Chai (Department of Graduate, Bengbu Medical College) ;
  • Yu Zhao (Health Management Center, Department of Endocrinology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College) ;
  • Zeng Zeng (Department of Ultrasound, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College) ;
  • Rui-zhong Ye (Department of Ultrasound, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College) ;
  • Qiao-hong Hu (Department of Ultrasound, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College) ;
  • Hong-feng He (Department of Ultrasound, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College) ;
  • Jung Hwan Baek (Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Cheng-zhong Peng (Department of Graduate, Bengbu Medical College)
  • Received : 2021.09.15
  • Accepted : 2022.03.09
  • Published : 2022.05.01
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: To assess the efficacy and safety of ultrasound (US)-guided radiofrequency ablation (RFA) in patients with primary hyperparathyroidism (PHPT). Materials and Methods: This prospective study enrolled 39 participants (14 male, 25 female; mean age, 59.5 ± 15.3 [range, 18-87] years) between September 1, 2018, and January 31, 2021. All participants had parathyroid lesions causing PHPT, proven biochemically and through imaging. The imaging features of the PHPT nodules, including the shape, margin, size, composition, and location, were evaluated before treatment. Serum intact parathyroid hormone, calcium, and phosphorus levels; parathyroid nodule volume; and PHPT-related symptoms were recorded before and after treatment. We calculated the technical success, biochemical cure, and clinical cure rates for these patients. Complications were evaluated during and after the ablation. Results: Complete ablation was achieved in 38 of the 39 nodules in the 39 enrolled participants. All the patients were treated in one session. The technical success rate was 97.4% (38/39). The mean follow-up duration was 13.2 ± 4.6 (range, 6.0-24.9) months. At 6 and 12 months post-RFA, the biochemical cure rates were 82.1% (32/39) and 84.4% (27/32), respectively, and the clinical cure rates were 100% (39/39) and 96.9% (31/32), respectively. Only 2.6% (1/39) of the patients had recurrent PHPT. At 1, 3, 6, and 12 months after technically successful RFA, 44.7% (17/38), 34.3% (12/35), 15.8% (6/38), and 12.5% (4/32) of participants, respectively, had elevated eucalcemic parathyroid hormone levels. Recurrent laryngeal nerve paralysis occurred in 5.1% (2/39) of the patients, who recovered spontaneously within 1-3 months. Conclusion: US-guided RFA was effective and safe for PHPT patients. RFA may be an alternative treatment tool for patients who cannot tolerate or refuse to undergo surgery.

Keywords

Acknowledgement

The authors gratefully acknowledge all participants.

References

  1. Bilezikian JP, Bandeira L, Khan A, Cusano NE. Hyperparathyroidism. Lancet 2018;391:168-178 https://doi.org/10.1016/S0140-6736(17)31430-7
  2. Wermers RA, Khosla S, Atkinson EJ, Achenbach SJ, Oberg AL, Grant CS, et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res 2006;21:171-177 https://doi.org/10.1359/JBMR.050910
  3. Yeh MW, Ituarte PH, Zhou HC, Nishimoto S, Liu IL, Harari A, et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab 2013;98:1122-1129 https://doi.org/10.1210/jc.2012-4022
  4. Walker MD, Silverberg SJ. Primary hyperparathyroidism. Nat Rev Endocrinol 2018;14:115-125
  5. Insogna KL. Primary hyperparathyroidism. N Engl J Med 2018;379:1050-1059 https://doi.org/10.1056/NEJMcp1714213
  6. Pierreux J, Bravenboer B. Normocalcemic primary hyperparathyroidism: a comparison with the hypercalcemic form in a tertiary referral population. Horm Metab Res 2018;50:797-802 https://doi.org/10.1055/a-0752-4533
  7. Schini M, Jacques RM, Oakes E, Peel NFA, Walsh JS, Eastell R. Normocalcemic hyperparathyroidism: study of its prevalence and natural history. J Clin Endocrinol Metab 2020;105:e1171-e1186 https://doi.org/10.1210/clinem/dgaa084
  8. Wilhelm SM, Wang TS, Ruan DT, Lee JA, Asa SL, Duh QY, et al. The American Association of endocrine surgeons guidelines for definitive management of primary hyperparathyroidism. JAMA Surg 2016;151:959-968 https://doi.org/10.1001/jamasurg.2016.2310
  9. Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 2014;99:3561-3569 https://doi.org/10.1210/jc.2014-1413
  10. Barczyn'ski M, Papier A, Kenig J, Nawrot I. A retrospective case-controlled study of video-assisted versus open minimally invasive parathyroidectomy. Wideochir Inne Tech Maloinwazyjne 2014;9:537-547
  11. Barczyn'ski M, Cichon' S, Konturek A, Cichon' W. Minimally invasive video-assisted parathyroidectomy versus open minimally invasive parathyroidectomy for a solitary parathyroid adenoma: a prospective, randomized, blinded trial. World J Surg 2006;30:721-731 https://doi.org/10.1007/s00268-005-0312-6
  12. Fan BQ, He XW, Chen HH, Zhang WM, Tang W. US-guided microwave ablation for primary hyperparathyroidism: a safety and efficacy study. Eur Radiol 2019;29:5607-5616 https://doi.org/10.1007/s00330-019-06078-y
  13. Jiang T, Chen F, Zhou X, Hu Y, Zhao Q. Percutaneous ultrasound-guided laser ablation with contrast-enhanced ultrasonography for hyperfunctioning parathyroid adenoma: a preliminary case series. Int J Endocrinol 2015;2015:673604
  14. Wei Y, Peng L, Li Y, Zhao ZL, Yu MA. Clinical study on safety and efficacy of microwave ablation for primary hyperparathyroidism. Korean J Radiol 2020;21:572-581 https://doi.org/10.3348/kjr.2019.0593
  15. Lang BHH, Woo YC, Chiu KW. High-intensity focused ablation (HIFU) of single benign thyroid nodule rarely alters underlying thyroid function. Int J Hyperthermia 2017;33:875-881 https://doi.org/10.1080/02656736.2017.1318456
  16. Ha EJ, Baek JH, Baek SM. Minimally invasive treatment for benign parathyroid lesions: treatment efficacy and safety based on nodule characteristics. Korean J Radiol 2020;21:1383-1392 https://doi.org/10.3348/kjr.2020.0037
  17. Hansler J, Harsch IA, Strobel D, Hahn EG, Becker D. Treatment of a solitary adenoma of the parathyroid gland with ultrasound-guided percutaneous Radio-Frequency-Tissue-Ablation (RFTA). Ultraschall Med 2002;23:202-206 https://doi.org/10.1055/s-2002-33154
  18. Wei Y, Peng CZ, Wang SR, He JF, Peng LL, Zhao ZL, et al. Effectiveness and safety of thermal ablation in the treatment of primary hyperparathyroidism: a multicenter study. J Clin Endocrinol Metab 2021;106:2707-2717 https://doi.org/10.1210/clinem/dgab240
  19. Khandelwal AH, Batra S, Jajodia S, Gupta S, Khandelwal R, Kapoor AK, et al. Radiofrequency ablation of parathyroid adenomas: safety and efficacy in a study of 10 patients. Indian J Endocrinol Metab 2020;24:543-550 https://doi.org/10.4103/ijem.IJEM_671_20
  20. Kwak JY, Kim EK, Moon HJ, Kim MJ, Ahn SS, Son EJ, et al. Parathyroid incidentalomas detected on routine ultrasound-directed fine-needle aspiration biopsy in patients referred for thyroid nodules and the role of parathyroid hormone analysis in the samples. Thyroid 2009;19:743-748
  21. Fang C, Konstantatou E, Mulholland NJ, Baroncini S, Husainy MA, Schulte KM, et al. A retrospective review of the role of B-mode and color Doppler ultrasonography in the investigation of primary hyperparathyroidism: features that differentiate benign from malignant lesions. Ultrasound 2018;26:110-117 https://doi.org/10.1177/1742271X18758516
  22. Bae JH, Choi HJ, Lee Y, Moon MK, Park YJ, Shin CS, et al. Preoperative predictive factors for parathyroid carcinoma in patients with primary hyperparathyroidism. J Korean Med Sci 2012;27:890-895 https://doi.org/10.3346/jkms.2012.27.8.890
  23. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985-1995: a National Cancer Data Base Report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1999;86:538-544 https://doi.org/10.1002/(SICI)1097-0142(19990801)86:3<538::AID-CNCR25>3.0.CO;2-K
  24. Ng A, Swanevelder J. Resolution in ultrasound imaging. Cont Educ Anaesth Crit Care Pain 2011;11:186-192 https://doi.org/10.1093/bjaceaccp/mkr030
  25. Hendee WR, Ritenour ER. Chapter 19. Ultrasound waves. In: Hendee WR, Ritenour ER, eds. Medical imaging physics. 4th ed. New York: Wiley, 2002:303-316
  26. Wang R, Jiang T, Chen Z, Chen J. Regression of calcinosis following treatment with radiofrequency thermoablation for severe secondary hyperparathyroidism in a hemodialysis patient. Intern Med 2013;52:583-587 https://doi.org/10.2169/internalmedicine.52.8454
  27. Jeong WK, Baek JH, Rhim H, Kim YS, Kwak MS, Jeong HJ, et al. Radiofrequency ablation of benign thyroid nodules: safety and imaging follow-up in 236 patients. Eur Radiol 2008;18:1244-1250 https://doi.org/10.1007/s00330-008-0880-6
  28. Zhuo L, Peng LL, Zhang YM, Xu ZH, Zou GM, Wang X, et al. US-guided microwave ablation of hyperplastic parathyroid glands: safety and efficacy in patients with end-stage renal disease-a pilot study. Radiology 2017;282:576-584 https://doi.org/10.1148/radiol.2016151875
  29. Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update. Radiology 2014;273:241-260 https://doi.org/10.1148/radiol.14132958
  30. Mauri G, Pacella CM, Papini E, Solbiati L, Goldberg SN, Ahmed M, et al. Image-guided thyroid ablation: proposal for standardization of terminology and reporting criteria. Thyroid 2019;29:611-618 https://doi.org/10.1089/thy.2018.0604
  31. Krawitz R, Glover A, Koneru S, Jiang J, Di Marco A, Gill AJ, et al. The significance of histologically "large normal" parathyroid glands in primary hyperparathyroidism. World J Surg 2020;44:1149-1155 https://doi.org/10.1007/s00268-019-05302-6
  32. Pal R, Arya AK, Aggarwal A, Singh P, Dahiya D, Sood A, et al. Weight gain after curative parathyroidectomy predicts increase in bone mineral density in patients with symptomatic primary hyperparathyroidism. Clin Endocrinol (Oxf) 2020;93:28-35 https://doi.org/10.1111/cen.14195
  33. Trebouet E, Bannani S, Wargny M, Leux C, Caillard C, Kraeber-Bodere F, et al. Mild sporadic primary hyperparathyroidism: high rate of multiglandular disease is associated with lower surgical cure rate. Langenbecks Arch Surg 2019;404:431-438 https://doi.org/10.1007/s00423-019-01782-1
  34. Ye J, Huang W, Huang G, Qiu Y, Peng W, Lan N, et al. Efficacy and safety of US-guided thermal ablation for primary hyperparathyroidism: a systematic review and meta-analysis. Int J Hyperthermia 2020;37:245-253 https://doi.org/10.1080/02656736.2020.1734673
  35. Liu F, Yu X, Liu Z, Qiao Z, Dou J, Cheng Z, et al. Comparison of ultrasound-guided percutaneous microwave ablation and parathyroidectomy for primary hyperparathyroidism. Int J Hyperthermia 2019;36:835-840 https://doi.org/10.1080/02656736.2019.1645365
  36. Baek JH, Lee JH, Sung JY, Bae JI, Kim KT, Sim J, et al. Complications encountered in the treatment of benign thyroid nodules with US-guided radiofrequency ablation: a multicenter study. Radiology 2012;262:335-342 https://doi.org/10.1148/radiol.11110416
  37. Fraser WD. Hyperparathyroidism. Lancet 2009;374:145-158 https://doi.org/10.1016/S0140-6736(09)60507-9
  38. Oltmann SC, Maalouf NM, Holt S. Significance of elevated parathyroid hormone after parathyroidectomy for primary hyperparathyroidism. Endocr Pract 2011;17 Suppl 1:57-62 https://doi.org/10.4158/EP10324.RA
  39. Kovatcheva R, Vlahov J, Stoinov J, Lacoste F, Ortuno C, Zaletel K. US-guided high-intensity focused ultrasound as a promising non-invasive method for treatment of primary hyperparathyroidism. Eur Radiol 2014;24:2052-2058 https://doi.org/10.1007/s00330-014-3252-4
  40. Zini M, Attanasio R, Cesareo R, Emmolo I, Frasoldati A, Gianotti L, et al. AME position statement: primary hyperparathyroidism in clinical practice. J Endocrinol Invest 2012;35(7 Suppl):2-21
  41. Kim JH, Baek JH, Lim HK, Ahn HS, Baek SM, Choi YJ, et al. 2017 thyroid radiofrequency ablation guideline: Korean Society of Thyroid Radiology. Korean J Radiol 2018;19:632-655 https://doi.org/10.3348/kjr.2018.19.4.632
  42. Dhillon VK, Rettig E, Noureldine SI, Genther DJ, Hassoon A, Al Khadem MG, et al. The incidence of vocal fold motion impairment after primary thyroid and parathyroid surgery for a single high-volume academic surgeon determined by pre- and immediate post-operative fiberoptic laryngoscopy. Int J Surg 2018;56:73-78 https://doi.org/10.1016/j.ijsu.2018.06.014
  43. Schneider M, Dahm V, Passler C, Sterrer E, Mancusi G, Repasi R, et al. Complete and incomplete recurrent laryngeal nerve injury after thyroid and parathyroid surgery: characterizing paralysis and paresis. Surgery 2019;166:369-374 https://doi.org/10.1016/j.surg.2019.05.019
  44. Joliat GR, Guarnero V, Demartines N, Schweizer V, Matter M. Recurrent laryngeal nerve injury after thyroid and parathyroid surgery: incidence and postoperative evolution assessment. Medicine (Baltimore) 2017;96:e6674
  45. Xiaoyin T, Ping L, Dan C, Min D, Jiachang C, Tao W, et al. Risk assessment and hydrodissection technique for radiofrequency ablation of thyroid benign nodules. J Cancer 2018;9:3058-3066 https://doi.org/10.7150/jca.26060